Eloxx Pharmaceuticals Company Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases.
Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Sumit Aggarwal |
Contact Details
Address: 480 Arsenal Way Watertown, Delaware 02472 United States | |
| Phone | 781 577 5300 |
| Website | eloxxpharma.com |
Stock Details
| Ticker Symbol | ELOX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US29014R1032 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sumit Aggarwal M.B.A. | President, Chief Executive Officer and Director |
| Daniel E. Geffken M.B.A. | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Barbara A. Ryan | Investor Relations Officer |
| Dr. Ali Hariri M.D. | Chief Medical Officer |